文献速递细菌感染、耐药与抗菌药物

耐多药铜绿假单胞菌对新型β-内酰胺/β-内酰胺酶抑制剂复合制剂表型与基因型药敏检测方法评估

Evaluation of Phenotypic and Genotypic Susceptibility Testing Methods for Newer β-lactam/β-lactamase Inhibitor Combinations in Multidrug Resistant Pseudomonas aeruginosa.
PubMed 文献 · J Infect Dis · 2026-01-01

该研究以183株耐多药铜绿假单胞菌临床分离株为对象,比较Sensititre与Phoenix商品化药敏板与微量肉汤稀释法(BMD)对头孢他啶-阿维巴坦(CZA)、头孢洛扎-他唑巴坦(CT)和亚胺培南-瑞来巴坦(IMR)的药敏检测性能,并用AMRFinderPlus预测基因型耐药决定因素。Sensititre板符合标准接受标准,Phoenix板分类一致率低;获得性β-内酰胺酶是BL/BLI耐药罕见原因,基因型预测表型耐药不可靠。

要点

  • Sensititre板对CZA、CT、IMR与BMD分类一致率分别为95.8%、90.1%、95.8%,达标准。
  • Phoenix板对CZA和CT分类一致率仅83.0%和85.7%,倾向低估CZA耐药。
  • 获得性β-内酰胺酶仅占初次患者分离株4.6%,基因型预测耐药假阴性率高。

核心结论

  • Sensititre板对三种BL/BLI药敏检测符合标准,Phoenix板分类一致率低。
  • 获得性β-内酰胺酶是BL/BLI耐药罕见原因,基因型预测表型耐药不可靠。

研究设计与样本

  • 采用183株耐多药铜绿假单胞菌临床分离株。
  • 以微量肉汤稀释法(BMD)为参考,评估Sensititre和Phoenix商品化药敏板。
  • 用AMRFinderPlus预测各分离株的基因型耐药决定因素。

主要发现

  • Sensititre板与BMD分类一致率:CZA 95.8%、CT 90.1%、IMR 95.8%。
  • Phoenix板与BMD分类一致率:CZA 83.0%、CT 85.7%,倾向低估CZA耐药。
  • AMRFinderPlus在4.6%的初次患者分离株中检出获得性β-内酰胺酶。
  • 基因型与BMD分类一致率:CZA 74.9%、CT 91.9%、IMR 90.7%。
  • 基因型检测对所有药物假阴性率过高,因许多表型耐药株无可识别基因型耐药决定因素。

关键数值与推荐

  • Sensititre板对CZA、CT、IMR分类一致率分别为95.8%、90.1%、95.8%,符合标准接受标准。
  • Phoenix板对CZA和CT分类一致率分别为83.0%和85.7%,对CT错误率在可接受范围内。
  • 基因型与BMD分类一致率:CZA 74.9%、CT 91.9%、IMR 90.7%,但假阴性率不可接受。

临床怎么用

  • 对耐多药铜绿假单胞菌BL/BLI药敏检测,Sensititre板性能优于Phoenix板。
  • 基因型预测不能替代表型药敏,尤其在获得性β-内酰胺酶低流行地区。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ceftazidime-avibactam (CZA), ceftolozane-tazobactam (CT), and imipenem-relebactam (IMR) are newer β-lactam/β-lactamase inhibitor (BL/BLI) combinations used for treatment of multidrug resistant (MDR) Pseudomonas aeruginosa, although resistance has already emerged. Optimal use of these agents relies on timely, accurate susceptibility testing results and understanding of local resistance mechanisms. METHODS: 183 MDR P. aeruginosa clinical isolates were used to evaluate the performance of commercial Sensititre and Phoenix panels for CZA, CT, and IMR susceptibility testing compared to broth microdilution (BMD). Genomic resistance determinants were also predicted for each isolate with AMRFinderPlus. RESULTS: Categorical agreement (CA) of the Sensititre panel compared to BMD was 95.8%, 90.1%, and 95.8% for CZA, CT, and IMR, respectively. CA of the Phoenix panel was 83.0% for CZA and 85.7% for CT. The Phoenix panel was biased toward under-calling CZA resistance while error rates were acceptable for CT by the error-rate-bound method. AMRFinderPlus identified acquired β-lactamases in 4.6% of first-time patient isolates. CA of genotype with BMD was 74.9% for CZA, 91.9% for CT, and 90.7% for IMR. However, all agents had unacceptably high VME rates using genotypic testing because many phenotypically resistant isolates had no identifiable genotypic resistance determinants. CONCLUSIONS: The Sensititre panel met standard acceptance criteria while the Phoenix panel had low CA for all tested BL/BLIs compared to BMD. Acquired β-lactamases were a rare cause of BL/BLI resistance. Further understanding of resistance mechanisms is required before phenotypic BL/BLI resistance can be reliably predicted from genotype, especially in settings where prevalence of acquired β-lactamases is low.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hall CW, Waglechner N, Choi E, et al. Evaluation of Phenotypic and Genotypic Susceptibility Testing Methods for Newer β-lactam/β-lactamase Inhibitor Combinations in Multidrug Resistant Pseudomonas aeruginosa. J Infect Dis. 2026. PMID: 41248977. doi:10.1093/infdis/jiaf585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。